Compare GSK plc (GSK) vs Microsoft (MSFT) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Microsoft (MSFT) trades at $400.42, up 4.02% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $4.27 exceeding the $4.06 forecast. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion. Analyst consensus is strongly bullish with an 80.49% buy rating and a $547.23 price target. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures persist.

Outlook remains positive driven by AI integration and cloud growth, but risks include heightened competition and macroeconomic volatility. The stock offers solid upside to the consensus target, supported by robust cash flow and dividend payments. Investors should weigh execution risks against long-term growth potential in the evolving tech landscape.